Apyx Medical Corp (APYX)

$3.325

-0.17

(-5%)▲

Market is closed - opens 7 PM, 22 Sep 2023

Insights on Apyx Medical Corp

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 35.39M → 13.56M (in $), with an average decrease of 35.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -17.42M → -994.0K (in $), with an average increase of 324.3% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 36.1% return, outperforming this stock by 69.4%

  • Vs SYK

    In the last 3 years, Stryker Corporation has given 40.3% return, outperforming this stock by 64.7%

Performance

  • $3.25
    $3.52
    $3.33
    downward going graph

    2.4%

    Downside

    Day's Volatility :7.67%

    Upside

    5.4%

    downward going graph
  • $1.31
    $7.97
    $3.33
    downward going graph

    60.66%

    Downside

    52 Weeks Volatility :83.56%

    Upside

    58.22%

    downward going graph

Returns

PeriodApyx Medical CorpSector (Health Care)Index (Russel 2000)
3 Months
-52.25%
0.0%
0.0%
6 Months
33.59%
3.0%
-0.5%
1 Year
-33.33%
7.2%
0.4%
3 Years
-24.41%
27.5%
19.1%

Highlights

Market Capitalization
155.9M
Book Value
$1.06
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.47
Wall Street Target Price
7.88
Profit Margin
-34.34%
Operating Margin TTM
-44.8%
Return On Assets TTM
-21.79%
Return On Equity TTM
-39.59%
Revenue TTM
47.4M
Revenue Per Share TTM
1.37
Quarterly Revenue Growth YOY
31.8%
Gross Profit TTM
29.1M
EBITDA
-20.5M
Diluted Eps TTM
-0.47
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.33
EPS Estimate Next Year
-0.46
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.11

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Apyx Medical Corp(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 136.99%

Current $3.33
Target $7.88

Company Financials

FY17Y/Y Change
Revenue
38.9M
↑ 6.16%
Net Income
-5.1M
↑ 28.15%
Net Profit Margin
-13.02%
↓ 2.24%
FY18Y/Y Change
Revenue
16.7M
↓ 57.09%
Net Income
64.0M
↓ 1364.5%
Net Profit Margin
383.61%
↑ 396.63%
FY19Y/Y Change
Revenue
28.2M
↑ 69.21%
Net Income
-19.7M
↓ 130.79%
Net Profit Margin
-69.79%
↓ 453.4%
FY20Y/Y Change
Revenue
27.7M
↓ 1.86%
Net Income
-11.9M
↓ 39.63%
Net Profit Margin
-42.93%
↑ 26.86%
FY21Y/Y Change
Revenue
48.5M
↑ 75.08%
Net Income
-15.2M
↑ 27.54%
Net Profit Margin
-31.27%
↑ 11.66%
FY22Y/Y Change
Revenue
44.5M
↓ 8.26%
Net Income
-23.2M
↑ 52.81%
Net Profit Margin
-52.09%
↓ 20.82%
Q1 FY22Q/Q Change
Revenue
12.5M
↓ 25.74%
Net Income
-5.9M
↑ 196.8%
Net Profit Margin
-47.59%
↓ 35.68%
Q2 FY22Q/Q Change
Revenue
10.3M
↓ 17.62%
Net Income
-5.4M
↓ 8.73%
Net Profit Margin
-52.72%
↓ 5.13%
Q3 FY22Q/Q Change
Revenue
9.1M
↓ 11.45%
Net Income
-5.8M
↑ 6.23%
Net Profit Margin
-63.24%
↓ 10.52%
Q4 FY22Q/Q Change
Revenue
35.4M
↑ 288.37%
Net Income
-17.4M
↑ 202.22%
Net Profit Margin
-49.21%
↑ 14.03%
Q1 FY23Q/Q Change
Revenue
16.7M
↓ 52.79%
Net Income
-3.5M
↓ 79.72%
Net Profit Margin
-21.14%
↑ 28.07%
Q2 FY23Q/Q Change
Revenue
13.6M
↓ 18.8%
Net Income
-994.0K
↓ 71.86%
Net Profit Margin
-7.33%
↑ 13.81%
FY17Y/Y Change
Total Assets
31.0M
↓ 11.74%
Total Liabilities
9.0M
↑ 0.78%
FY18Y/Y Change
Total Assets
95.6M
↑ 208.54%
Total Liabilities
7.8M
↓ 12.44%
FY19Y/Y Change
Total Assets
84.7M
↓ 11.36%
Total Liabilities
13.5M
↑ 71.97%
FY20Y/Y Change
Total Assets
74.1M
↓ 12.55%
Total Liabilities
10.3M
↓ 23.98%
FY21Y/Y Change
Total Assets
68.7M
↓ 7.27%
Total Liabilities
14.7M
↑ 43.5%
FY22Y/Y Change
Total Assets
51.8M
↓ 24.66%
Total Liabilities
14.0M
↓ 4.96%
Q1 FY22Q/Q Change
Total Assets
63.0M
↓ 8.33%
Total Liabilities
13.2M
↓ 10.59%
Q2 FY22Q/Q Change
Total Assets
59.5M
↓ 5.6%
Total Liabilities
13.3M
↑ 1.17%
Q3 FY22Q/Q Change
Total Assets
55.3M
↓ 7.07%
Total Liabilities
13.1M
↓ 1.93%
Q4 FY22Q/Q Change
Total Assets
51.8M
↓ 6.32%
Total Liabilities
14.0M
↑ 7.13%
Q1 FY23Q/Q Change
Total Assets
56.8M
↑ 9.67%
Total Liabilities
20.6M
↑ 47.12%
Q2 FY23Q/Q Change
Total Assets
62.4M
↑ 9.94%
Total Liabilities
25.7M
↑ 24.92%
FY17Y/Y Change
Operating Cash Flow
-3.7M
↑ 30.56%
Investing Cash Flow
-624.0K
↑ 118.18%
Financing Cash Flow
-179.0K
↓ 103.1%
FY18Y/Y Change
Operating Cash Flow
-21.0M
↑ 467.25%
Investing Cash Flow
29.3M
↓ 4795.67%
Financing Cash Flow
-2.5M
↑ 1292.18%
FY19Y/Y Change
Operating Cash Flow
-18.5M
↓ 12.07%
Investing Cash Flow
60.5M
↑ 106.62%
Financing Cash Flow
147.0K
↓ 105.9%
FY20Y/Y Change
Operating Cash Flow
-16.1M
↓ 13.04%
Investing Cash Flow
-581.0K
↓ 100.96%
Financing Cash Flow
-73.0K
↓ 149.66%
FY21Y/Y Change
Operating Cash Flow
-10.4M
↓ 34.96%
Investing Cash Flow
-723.0K
↑ 24.44%
Financing Cash Flow
24.0K
↓ 132.88%
FY22Y/Y Change
Operating Cash Flow
-20.3M
↑ 94.09%
Investing Cash Flow
-1.0M
↑ 39.7%
Financing Cash Flow
217.0K
↑ 804.17%
Q1 FY22Q/Q Change
Operating Cash Flow
-4.5M
↓ 2211.21%
Investing Cash Flow
-279.0K
↓ 15.96%
Financing Cash Flow
98.0K
↓ 351.28%
Q2 FY22Q/Q Change
Operating Cash Flow
-5.9M
↑ 29.97%
Investing Cash Flow
-401.0K
↑ 43.73%
Financing Cash Flow
2.0K
↓ 97.96%
Q3 FY22Q/Q Change
Operating Cash Flow
-5.4M
↓ 8.72%
Investing Cash Flow
-188.0K
↓ 53.12%
Financing Cash Flow
127.0K
↑ 6250.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-14.9M
↑ 178.36%
Investing Cash Flow
-142.0K
↓ 24.47%
Financing Cash Flow
90.0K
↓ 29.13%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.9M
↓ 87.39%
Investing Cash Flow
-110.0K
↓ 22.54%
Financing Cash Flow
8.1M
↑ 8913.33%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.9M
↑ 157.95%
Investing Cash Flow
7.1M
↓ 6564.55%
Financing Cash Flow
46.0K
↓ 99.43%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Apyx Medical Corp
Apyx Medical Corp
-23.58%
33.59%
-33.33%
-24.41%
-52.12%
Stryker Corporation
Stryker Corporation
4.61%
3.9%
36.01%
42.41%
65.6%
Boston Scientific Corp.
Boston Scientific Corp.
7.3%
10.77%
36.07%
40.34%
43.24%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-5.74%
-11.97%
-15.57%
-11.66%
40.45%
Abbott Laboratories
Abbott Laboratories
-3.46%
1.98%
-0.37%
-5.35%
45.23%
Medtronic Plc
Medtronic Plc
-0.16%
0.31%
-4.96%
-22.25%
-16.73%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Apyx Medical Corp
Apyx Medical Corp
NA
NA
NA
-0.33
-0.4
-0.22
0.0
1.06
Stryker Corporation
Stryker Corporation
40.82
40.82
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
88.69
88.69
2.53
1.99
0.05
0.04
0.0
12.46
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
31.84
31.84
3.07
2.55
0.22
0.12
0.0
10.49
Abbott Laboratories
Abbott Laboratories
34.23
34.23
18.76
4.39
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
30.07
30.07
3.04
5.28
0.07
0.04
0.03
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Apyx Medical Corp
Apyx Medical Corp
Buy
$155.9M
-52.12%
NA
-34.34%
Stryker Corporation
Stryker Corporation
Buy
$109.7B
65.6%
40.82
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$79.2B
43.24%
88.69
6.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$43.7B
40.45%
31.84
24.56%
Abbott Laboratories
Abbott Laboratories
Buy
$174.0B
45.23%
34.23
12.83%
Medtronic Plc
Medtronic Plc
Buy
$109.9B
-16.73%
30.07
11.47%

Institutional Holdings

  • Archon Capital Management LLC

    9.96%

  • Divisadero Street Capital Management, LP

    6.59%

  • RTW INVESTMENTS, LLC

    5.13%

  • Royce & Associates, LP

    4.63%

  • Vanguard Group Inc

    4.27%

  • AIGH Capital Management, LLC

    3.66%

Corporate Announcements

  • Apyx Medical Corp Earnings

    Apyx Medical Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

apyx medical corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. it operates in two segments, advanced energy and original equipment manufacturing (oem). the company develops j-plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. it markets and sells helium plasma technology under the renuvion brand name in the cosmetic surgery market and under the j-plasma brand name in the hospital surgical market. the company's renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the j-plasma system allows surgeons to operate in eliminating unintended tissue trauma. it also designs, develops, manufactures, and sells electrosurgical and oem generators and related accessories for medical device manufacturers. the company was formerly known as bovie medical corporation and changed

Organization
Apyx Medical Corp
Employees
276
CEO
Mr. Charles D. Goodwin II
Industry
Health Technology

Discover More

FAQs